Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Uwe Zangemeister-Wittke

Showing results (1-10 of 62) with videos related to

Pageof 7
Sort By:
Annals of the New York Academy of Sciences|January 31, 2004
Antisense to apoptosis inhibitors facilitates chemotherapy and TRAIL-induced death signalingUwe Zangemeister-Wittke
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology|April 4, 2006
Antibodies for targeted cancer therapy -- technical aspects and clinical perspectivesUwe Zangemeister-Wittke
Critical Reviews in Oncology/Hematology|June 15, 2007
Targeting the conversion of ceramide to sphingosine 1-phosphate as a novel strategy for cancer therapyAndrea Huwiler, Uwe Zangemeister-Wittke
Pharmacology & Therapeutics|November 12, 2017
The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectivesAndrea Huwiler, Uwe Zangemeister-Wittke
The Lancet. Oncology|November 9, 2002
Antisense therapy for cancer--the time of truthBurkhard Jansen, Uwe Zangemeister-Wittke
Lung Cancer (Amsterdam, Netherlands)|July 18, 2003
Antisense oligonucleotides for cancer therapy-an overviewRolf A Stahel, Uwe Zangemeister-Wittke
Cell Cycle (Georgetown, Tex.)|August 25, 2004
An IAP in action: the multiple roles of survivin in differentiation, immunity and malignancyUwe Zangemeister-Wittke, Hans-Uwe Simon
Molecular Carcinogenesis|March 12, 2013
AMR-Me inhibits PI3K/Akt signaling in hormone-dependent MCF-7 breast cancer cells and inactivates NF-κB in hormone-independent MDA-MB-231 cellsThangaiyan Rabi, Andrea Huwiler, Uwe Zangemeister-Wittke
Bioconjugate Chemistry|December 23, 2011
Facile double-functionalization of designed ankyrin repeat proteins using click and thiol chemistriesManuel Simon, Uwe Zangemeister-Wittke, Andreas Plückthun
Cancer Treatment Reviews|November 19, 2002
Circulating DNA: a new diagnostic gold mine?Annemarie Ziegler, Uwe Zangemeister-Wittke, Rolf A Stahel
Pageof 7

Showing results (1-10 of 62) with videos related to

Sort By:
Pageof 7
Annals of the New York Academy of Sciences|January 31, 2004
Antisense to apoptosis inhibitors facilitates chemotherapy and TRAIL-induced death signalingUwe Zangemeister-Wittke
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology|April 4, 2006
Antibodies for targeted cancer therapy -- technical aspects and clinical perspectivesUwe Zangemeister-Wittke
Critical Reviews in Oncology/Hematology|June 15, 2007
Targeting the conversion of ceramide to sphingosine 1-phosphate as a novel strategy for cancer therapyAndrea Huwiler, Uwe Zangemeister-Wittke
Pharmacology & Therapeutics|November 12, 2017
The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectivesAndrea Huwiler, Uwe Zangemeister-Wittke
The Lancet. Oncology|November 9, 2002
Antisense therapy for cancer--the time of truthBurkhard Jansen, Uwe Zangemeister-Wittke
Lung Cancer (Amsterdam, Netherlands)|July 18, 2003
Antisense oligonucleotides for cancer therapy-an overviewRolf A Stahel, Uwe Zangemeister-Wittke
Cell Cycle (Georgetown, Tex.)|August 25, 2004
An IAP in action: the multiple roles of survivin in differentiation, immunity and malignancyUwe Zangemeister-Wittke, Hans-Uwe Simon
Molecular Carcinogenesis|March 12, 2013
AMR-Me inhibits PI3K/Akt signaling in hormone-dependent MCF-7 breast cancer cells and inactivates NF-κB in hormone-independent MDA-MB-231 cellsThangaiyan Rabi, Andrea Huwiler, Uwe Zangemeister-Wittke
Bioconjugate Chemistry|December 23, 2011
Facile double-functionalization of designed ankyrin repeat proteins using click and thiol chemistriesManuel Simon, Uwe Zangemeister-Wittke, Andreas Plückthun
Cancer Treatment Reviews|November 19, 2002
Circulating DNA: a new diagnostic gold mine?Annemarie Ziegler, Uwe Zangemeister-Wittke, Rolf A Stahel
Pageof 7